Quantcast
Get breaking news alerts via email

Click here to manage your alerts
Editorial: Primary Children’s takes welcome step toward understanding

Finally, some research on marijuana.

First Published Jul 03 2014 05:43 pm • Last Updated Jul 03 2014 05:47 pm

Seldom does an advanced society pride itself on its ignorance. But, for nearly half a century, the laws of the United States have effectively prevented any honest and useful study of the benefits and harms of various forms of the marijuana plant.

Slowly, that attitude is changing. And Utah’s Primary Children’s Hospital is to be one of those to take a small but important step toward an understanding that can save lives.

Join the Discussion
Post a Comment

Since Congress passed Controlled Substances Act of 1970, American science has been hobbled by the wholly unsupported assumption that marijuana, aka cannabis, is a totally useless and entirely dangerous substance. Not because of any research or scientific input, but because Congress said so.

This led to the placement of marijuana on the list of what the Drug Enforcement Agency calls "Schedule 1" substances, alongside heroin and LSD. And, as long as marijuana sat on that list, real research on what it and its extracts could do for us, and might do to us, was basically impossible.

Hearts and minds have been opened in recent years, though, by more and more people who came forward to say that they, their loved ones, or their patients, had found welcome relief from such maladies as glaucoma, the crippling side-effects of anti-cancer chemotherapy and, more recently, epileptic seizures.

Just as closed minds kept marijuana out of the labs for so long, it was an open-hearted hope felt by a majority of the Utah Legislature that led to the passage of a law allowing the use of a particular extract of the marijuana plant to treat some forms of debilitating seizures suffered mostly by young children.

Another cannabis-based substance is to be the subject of the study that Children’s Research is putting together, awaiting final DEA approval. Even if the work there shows that the drug it is to investigate, a British-made extract called Epidiolex, works, that drug will remain a proprietary, and expensive, treatment. Today, the drug would cost families $10,000 to $15,000 a year.

That is in stark contrast to the substance the Legislature was interested in setting free, an extract called CBD oil, now available from a Colorado-based cooperative for $200 a month.

The problem with both of those hopeful concoctions, and many others, is that we still lack good data, based on hard research, that will tell us what substances, at what doses, for which patients, and at what prices, will fulfill this promise. Utah can be proud that some of that work is being done here.




Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment


About Reader Comments


Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Videos
Jobs
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Access your e-Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.